Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    22237781 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Condition: Papillary Renal Cell Carcinoma
Intervention: Drug: INC280
2 Recruiting Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Drug: oxaliplatin and gemcitabine;   Drug: capecitabine
3 Recruiting Safety and Efficacy Study of Five-fraction Stereotactic Body Radiation Therapy to Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Device: Cyberknife
4 Recruiting Combination of Stereotactic Body Radiation Therapy With S-1 for Treating Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Other: combination of Cyberknife with S-1
5 Active, not recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
6 Recruiting trūFreeze® Spray Cryotherapy Patient Registry
Conditions: Barrett Esophagus;   Esophageal Dysplasia;   Esophageal Neoplasm;   Esophageal Stenosis;   Bronchial Neoplasm;   Stenosis of Bronchus or Trachea
Intervention: Device: truFreeze Spray Cryotherapy
7 Recruiting Radiotherapy for Oligometastatic Prostate Cancer
Condition: Oligometastatic Prostate Cancer
Intervention: Radiation: SBRT/SHRT

Study has passed its completion date and status has not been verified in more than two years.